Therapeutic Drug Monitoring of Long Acting Rilpivirine and Cabotegravir for Treatment of HIV-1 Infection – A Case Series of Five Patients with One Virologic Failure after Development of Two-Class Resistance

IF 3.8 4区医学 Q2 IMMUNOLOGY

Open Forum Infectious Diseases Pub Date : 2024-08-22 DOI:10.1093/ofid/ofae480

Jacob Gerstenberg, Hartwig Klinker, Michael Baier, Amrei von Braun, Ulrich Seybold, Carlotta Helbig, Martin Däumer, Klaus Korn, Christoph Stephan, Benjamin T Schleenvoigt

引用次数: 0

Abstract

Virologic failure of long-acting rilpivirine/cabotegravir is rare but may result in severely limited treatment options. Known risk factors cannot predict all cases. Therapeutic drug monitoring (TDM) may help identify patients-at-risk, but reliable thresholds are missing. We report retrospective TDM in a cohort of five patients, including one virological failure.

查看原文本刊更多论文

用于治疗 HIV-1 感染的长效利匹韦林和卡博替拉韦的治疗药物监测 - 五名患者在出现两类抗药性后出现一次病毒学失败的病例系列研究

长效利匹韦林/卡博替拉韦的病毒学失败非常罕见，但可能导致治疗方案严重受限。已知的风险因素无法预测所有病例。治疗药物监测（TDM）可帮助识别高危患者，但缺乏可靠的阈值。我们报告了一组五名患者的回顾性 TDM，其中包括一名病毒学失败患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Open Forum Infectious Diseases Medicine-Neurology (clinical)

CiteScore

6.70

自引率

4.80%

发文量

630

审稿时长

9 weeks

期刊介绍： Open Forum Infectious Diseases provides a global forum for the publication of clinical, translational, and basic research findings in a fully open access, online journal environment. The journal reflects the broad diversity of the field of infectious diseases, and focuses on the intersection of biomedical science and clinical practice, with a particular emphasis on knowledge that holds the potential to improve patient care in populations around the world. Fully peer-reviewed, OFID supports the international community of infectious diseases experts by providing a venue for articles that further the understanding of all aspects of infectious diseases.